
RATIONALE 302: Randomized, Phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma

Lin Shen,¹ Ken Kato,² Sung-Bae Kim,³ Jaffer Ajani,⁴ Kuaile Zhao,⁵ Zhiyong He,⁶ Xinmin Yu,⁷ Yonqian Shu,⁸ Qi Luo,⁹ Jufeng Wang,¹⁰ Zhendong Chen,¹¹ Zuoxing Niu,¹² Jong-Mu Sun,¹³ Chen-Yuan Lin,¹⁴ Hiroki Hara,¹⁵ Roberto Pazo-Cid,¹⁶ Christophe Borg,¹⁷ Liyun Li,¹⁸ Aiyang Tao,¹⁸ Eric Van Cuttesm¹⁹ "Bar Network of Execution Shu,¹⁸ Columers, Network Centre Universe, Network Centre Uni

Introduction

- Advanced or metastatic esophageal squamous cell carcinoma (ESCC) has a poor prognosis, with an estimated 5-year survival rate of ~5%¹
- Tislelizumab is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and specificity for PD-1, engineered to minimize binding to FcqR on macrophages to limit antibody-dependent phagocytosis, a mechanism of T-cell clearance and a potential mechanism of resistance to anli-PD-1 therapy²
- Tislelizumab monotherapy has demonstrated antitumor activity in patients with solid tumors, including ESCC³⁻⁵
- Here, we report the primary results of a global Phase 3 study (NCT03430843) that investigated the effect of second-line tislelizumab compared with chemotherapy on overall survival (OS) in adult batients with advanced or metastatic ESCC



```
The study required ~40.0 death events to achieve 82% power to detect a HR of 0.75 at 0.025 significance level (1-sided) for the 
primary endpoint of OS in all randomized patients (ITT analysis as 
if OS in all randomized patients (ITT analysis et) was statistically significant, OS in patients with vCPS ≥ 10% (PD-L1+ analysis
```

If US in all randomized patients (I11 analysis set) was statistically significant, US in patients with VLPS 2 10% (PD-L1+ analysis set) was tested sequentially.

The Japer IXD mgHr IV to option constitution/weakly daming for Sweaks, Disease by one weak of water. You Japer. 70 mgHr IV DWD. DBC, doubt of marging in Sampara Decomposition Science (SSC), camping in spannars and clicardonnes, HR, Instand mice (TT, Interét IV, Interwander, DRR, dejachte response nets, CS, coveral survival; PFS, progression-free survival; OW, once weakly; DWW, wavy three weaks; VX, Streamond response nets cover a survival; PFS, progression-free survival; OW, once weakly; DWW, wavy three weaks;

Results

- 512 patients were randomized (256 to tislelizumab and 256 to chemotherapy) from 132 sites in 11 countries/regions in Asia, Europe, and North America. Treatment was received by 255 patients (99.6%) for tislelizumab and 240 patients (93.8%) for chemotherapy
- At the data cut-off of final analysis (Dec 1, 2020):
- Median (range) follow-up in months was 8.5 (0.2-31.7) for tislelizumab and 5.8 (0-30.8) for chemotherapy
- 16 patients (6.3%) remained on treatment with tislelizumab vs 1 patient (0.4%) with chemotherapy

Table 1. Patient baseline characteristics in all randomized patients

Characteristic	Tislelizumab (n=256)	Chemotherapy (n=256)
Median age (range), years	62.0 (40-86)	63.0 (35-81)
Male, n (%)	217 (84.8)	215 (84.0)
Region, n (%)		
Asia	201 (78.5)	203 (79.3)
Europe/North America	55 (21.5)	53 (20.7)
ECOG PS, n (%)		
0	66 (25.8)	60 (23.4)
1	190 (74.2)	196 (76.6)
PD-L1 status, n (%)		
vCPS ≥ 10%	89 (34.8)	68 (26.6)
vCPS < 10%	116 (45.3)	140 (54.7)
Unknown	51 (19.9)	48 (18.8)
Disease status at baseline, n (%)		
Locally advanced	5 (2.0)	20 (7.8)
Metastatic	251 (98.0)	236 (92.2)
Prior therapies, n (%)		
Surgery	94 (36.7)	99 (38.7)
Radiotherapy	169 (66.0)	163 (63.7)
Platinum-based chemotherapy	249 (97.3)	252 (98.4)

Conclusions

100

90

80 -

70 -

60 •

50 -

40 -

30

20 -

10

Overall survival (% of patients)

 Tislelizumab demonstrated a statistically significant and clinically meaningful improvement in OS vs chemotherapy in advanced or metastatic ESCC patients whose tumor progressed during or after first line treatment

 Survival benefit was observed across pre-defined subgroups, including PD-L1 expression status, race and region


Tislelizumab resulted in higher and more durable antitumor response than chemotherapy


 Tislelizumab showed a favorable safety profile compared with chemotherapy, with no new safety signals identified

 Tislelizumab represents a potential new second-line treatment option for patients with advanced or metastatic ESCC

Overall survival

- Tislelizumab significantly improved OS compared to chemotherapy in all randomized patients, as well as in patients with vCPS ≥ 10%:
- A 30% reduction in the risk of death (HR 0.70, 95% confidence interval [CI]: 0.57– 0.85, p=0.0001), with a 2.3 month improvement in median OS in all randomized patients was observed (Figure 2)
- A 46% reduction in the risk of death (HR 0.54, 95% CI: 0.36–0.79, p=0.0006), with a 3.5 month improvement in median OS in patients with PD-L1 vCPS ≥ 10% was observed (Figure 3)
- Survival benefit was consistently observed across pre-defined subgroups, including
 PD-L1 expression status, race and region (Figure 4)
 Figure 3, Kaplan-Meier old of OS in patients with vCPS ≥ 10% (key secondary endpoint)





Events (% of patients)

Median OS (95% CI),

months'

P-value

HR (95% CI)

Figure 2. Kaplan-Meier plot of OS in all randomized patients (primary endpoint)

12-month

37.4

23.7

rate

6-month

rate

62.3

Smoking status Former/cume Nonemoker Chemotherapy Pacitized 139/188 -----0.67 (0.54-0.84) 0.75 (0.55-1.97) 197/25 68/85 Ŧ 0.76(0.58-1.0 Docetore Innotecar ECOG PS 45/64 45/63 0.73 (0.48-1.11 Region 073/059-09 162 / 201 171/203 tace Asian and other 164/203 179/212 0.72(0.59-0.9 -----34/44 Daseline PD-L1 stat vCPS ≥ 10% vCPS < 10% 61/89 97/116 58/68 0.53 (0.37-0.77

HR was based on an unsinelled Cox regression model including invariantials covariate
 Trisfelizumab better
 Confidence interval; ECOX PS; Eastern Cooperative Decology Group performance score; HR heard ratio; PDL 1; programmed death ligend 1;

Progression-free survival

 The PFS Kaplan-Meier curves began to separate approximately 3 months after randomization in favor of tislelizumab (Figure 5)

Figure 5. Kaplan-Meier plot of PFS in all randomized patients (secondary endpoint)



Response rate and duration

Tislelizumab was associated with a greater ORR (20.3% vs 9.8%; odds ratio 2.4, 95% Cl 1.4-4.0) and a more durable tumor response (median DoR: 7.1 months vs 4.0 months) than chemotherapy (Table 2)

Table 2. Summary of antitumor activity per RECIST v1.1 (investigator-assessed) in all randomized patients (secondary endpoint)

	Tislelizumab (n=256)	Chemotherapy (n=256)
ORR		
n	52	25
% (95% CI)*	20.3 (15.6-25.8)	9.8 (6.4-14.1)
Odds ratio (95% CI)†	2.4 (1.4-4.0)	
Best overall response, n (%)		
Complete response	5 (2.0)	1 (0.4)
Partial response	47 (18.4)	24 (9.4)
Stable disease	68 (26.6)	82 (32.0)
Progressive disease	116 (45.3)	86 (33.6)
Not evaluable [‡]	20 (7.8)	63 (24.6)
Median DoR (95% CI), months ⁵	7.1 (4.1-11.3)	4.0 (2.1-8.2)
Patients with ongoing response, n/N (%)	10/52 (19.2)	0/25 (0)

*Ino-cost costs: La tera cancarea uang ucapes-Peranon method. (Calculated uaing the Cachan-Maeted-Hancard Chi-square teat, Hockafing those with no par-baseline assessment's an unrestande postanties assessment, Madares area estimated by Replan-Maier method with 20%. Cite astimated using the method of Biochenger and Costley. DOR analysis include patients with Objective response (Complete or partiel response) (2. conditional interus), Cite, Anatorial or response (Complete or partiel response and cost and cost and cost (2. conditional interus), Cite, Anatorial or response (Cost), Cost and and cost and and cost and cos

Safety

Tislelizumab Chemotherapy

8.6 (7.5-10.4) 6.3 (5.3-7.0)

0.70 (0.57-0.85)

0.0001

Tislelizumah

(n=256)

213 (83.2)

(n=256)

197 (77.0)

Chemotherapy

Tislelizumab showed a favorable safety profile compared with chemotherapy, with no new safety signals identified (Tables 3 and 4)

Table 3. Summary of AEs

Tislelizumab (n=255)	Chemotherapy (n=240)
244 (95.7) / 187 (73.3)	236 (98.3) / 225 (93.8)
118 (46.3) / 48 (18.8)	163 (67.9) / 134 (55.8)
105 (41.2)/36 (14.1)	105 (43.8)/ 47 (19.6)
49 (19.2) / 17 (6.7)	64 (26.7) / 33 (13.8)
14 (5.5) / 5 (2.0)	14 (5.8) / 7 (2.9)
	(n=255) 244 (95.7) / 187 (73.3) 118 (46.3) / 48 (18.8) 105 (41.2) / 36 (14.1) 49 (19.2) / 17 (6.7)

All Alls are instituted on the second of the

Table 4. Treatment-related AEs reported in ≥ 10% of patients*

Preferred term, n (%)	Tislelizumab (n=255)	Chemotherapy (n=240)
Aspartate aminotransferase increased	29 (11.4)	9 (3.8)
Anemia	28 (11.0)	83 (34.6)
Hypothyroidism	26 (10.2)	0 (0.0)
Fatigue	19 (7.5)	33 (13.8)
Decreased appetite	16 (6.3)	75 (31.3)
Diarrhea	14 (5.5)	66 (27.5)
Asthenia	12 (4.7)	28 (11.7)
Malaise	10 (3.9)	35 (14.6)
Weight decreased	8 (3.1)	25 (10.4)
Vausea	7 (2.7)	66 (27.5)
Leukopenia	7 (2.7)	30 (12.5)
White blood cell count decreased	5 (2.0)	98 (40.8)
Vomiting	4 (1.6)	43 (17.9)
Constipation	4 (1.6)	25 (10.4)
leutrophil count decreased	3 (1.2)	94 (39.2)
leutropenia	2 (0.8)	31 (12.9)
Alopecia	0 (0.0)	42 (17.5)

In either treatment group TRAE: included AEs their were considered by the investigetor to be related to study drug or AEs with a missing causality If where a were't TRAE: Investment-related adverse event

References

ovlader N. et al. SEER Cancer Statistics Review. 1975-2017. National Cancer Institute.	3. Denai J. et
LISA (2020), https://www.cancer.opv/cat/1975_2017/	4. Shen L. et
ang T. et al. Cancer Immunol Immunother 2018;67:1079-90	5. Xu J. et al.

Acknowledgments

This study is sponsored by BelGeree, List Medical writing support for the development of this poster and associated abstract, under direction of the sufform, was provided by Kinsty Milar, MS of Ashfeld Med/Cerms, an Ashfeld Health company, and was funded by BelGeree List Logistical support was provided by Pelcition Advantage, LLC, an OPEN Health company, Panipper NJ, and funded by BelGeree.

Author contact details: linshenpku@163.com (Lin Shen)